A Pilot Trial of an Accelerated Immunization Schedule With ALVAC-pp65 (vCP260) for Inducing CMV-Specific Immunity in Stem Cell Allotransplant Donors and Healthy Volunteers.

Trial Profile

A Pilot Trial of an Accelerated Immunization Schedule With ALVAC-pp65 (vCP260) for Inducing CMV-Specific Immunity in Stem Cell Allotransplant Donors and Healthy Volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Cytomegalovirus vaccine vCP260 (Primary)
  • Indications Cytomegalovirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Dec 2009 Actual patient number (38) added as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 17 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top